Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a ...

Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

Vaccines and monoclonal antibodies are reducing RSV hospitalizations, but high costs and limited access in low-income ...

Nirsevimab demonstrated 89% effectiveness against medically attended RSV-associated acute respiratory illness and 93% effectiveness against RSV-associated hospitalizations, although only 442 ...

Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while Health Canada has approved an immunization that can protect all babies from the ...

State health officials encourage New Yorkers to get vaccines that protect against flu, COVID-19, and respiratory syncytial virus (RSV).

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and ...

RSV cases drop in Alaska's Yukon-Kuskokwim region, Ketchikan airport parking is tight, hunters urged to try lead-free ammo, ...

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.